These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38319964)

  • 1. Design of universal Ebola virus vaccine candidates via immunofocusing.
    Xu D; Powell AE; Utz A; Sanyal M; Do J; Patten JJ; Moliva JI; Sullivan NJ; Davey RA; Kim PS
    Proc Natl Acad Sci U S A; 2024 Feb; 121(7):e2316960121. PubMed ID: 38319964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of universal Ebola virus vaccine candidates
    Xu D; Powell AE; Utz A; Sanyal M; Do J; Patten JJ; Moliva JI; Sullivan NJ; Davey RA; Kim PS
    bioRxiv; 2023 Oct; ():. PubMed ID: 37904982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
    Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
    J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
    Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 7. Enhanced
    Chabot S; Gimie Y; Obeid K; Kim J; Meseda CA; Konduru K; Kaplan G; Sheng Fowler L; Weir JP; Peden K; Major ME
    J Virol; 2022 Sep; 96(18):e0116621. PubMed ID: 36069549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
    Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
    Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimerization of Ebola GPΔmucin on protein nanoparticle vaccines has minimal effect on elicitation of neutralizing antibodies.
    Powell AE; Xu D; Roth GA; Zhang K; Chiu W; Appel EA; Kim PS
    Front Immunol; 2022; 13():942897. PubMed ID: 36091016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
    Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
    J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
    Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
    Gilchuk P; Guthals A; Bonissone SR; Shaw JB; Ilinykh PA; Huang K; Bombardi RG; Liang J; Grinyo A; Davidson E; Chen EC; Gunn BM; Alter G; Saphire EO; Doranz BJ; Bukreyev A; Zeitlin L; Castellana N; Crowe JE
    Front Immunol; 2021; 12():706757. PubMed ID: 34335620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
    Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
    PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.
    Callendret B; Vellinga J; Wunderlich K; Rodriguez A; Steigerwald R; Dirmeier U; Cheminay C; Volkmann A; Brasel T; Carrion R; Giavedoni LD; Patterson JL; Mire CE; Geisbert TW; Hooper JW; Weijtens M; Hartkoorn-Pasma J; Custers J; Grazia Pau M; Schuitemaker H; Zahn R
    PLoS One; 2018; 13(2):e0192312. PubMed ID: 29462200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses.
    Wu F; Zhang S; Zhang Y; Mo R; Yan F; Wang H; Wong G; Chi H; Wang T; Feng N; Gao Y; Xia X; Zhao Y; Yang S
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31947873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad antibody and T cell responses to Ebola, Sudan, and Bundibugyo ebolaviruses using mono- and multi-valent adjuvanted glycoprotein vaccines.
    Felgner J; Clarke E; Hernandez-Davies JE; Jan S; Wirchnianski AS; Jain A; Nakajima R; Jasinskas A; Strahsburger E; Chandran K; Bradfute S; Davies DH
    Antiviral Res; 2024 May; 225():105851. PubMed ID: 38458540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice.
    Chen T; Li D; Song Y; Yang X; Liu Q; Jin X; Zhou D; Huang Z
    Antiviral Res; 2017 Sep; 145():54-59. PubMed ID: 28733113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.
    Luczkowiak J; Arribas JR; Gómez S; Jiménez-Yuste V; de la Calle F; Viejo A; Delgado R
    Virus Res; 2016 Feb; 213():224-229. PubMed ID: 26739425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.
    Bounds CE; Kwilas SA; Kuehne AI; Brannan JM; Bakken RR; Dye JM; Hooper JW; Dupuy LC; Ellefsen B; Hannaman D; Wu H; Jiao JA; Sullivan EJ; Schmaljohn CS
    PLoS One; 2015; 10(9):e0137786. PubMed ID: 26422247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.
    DiNapoli JM; Yang L; Samal SK; Murphy BR; Collins PL; Bukreyev A
    Vaccine; 2010 Dec; 29(1):17-25. PubMed ID: 21034822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.